Caveolin 1 and Caveolin 2 are associated with breast cancer basal-like and triple-negative immunophenotype
Open Access
- 8 July 2008
- journal article
- research article
- Published by Springer Nature in British Journal of Cancer
- Vol. 99 (2) , 327-334
- https://doi.org/10.1038/sj.bjc.6604463
Abstract
Caveolin-1 (CAV1) and caveolin 2 (CAV2) are the principal structural proteins of caveolae, sphingolipid and cholesterol-rich invaginations of the plasma membrane involved in vesicular trafficking and signal transduction. Over the recent years there has been controversy about their role in breast cancer and their suitability as markers of basal-like phenotype. Caveolin-1 and CAV2 protein expression was assessed on a tissue microarray containing 880 unselected invasive breast cancer cases, by means of immunohistochemistry. Caveolin-1 and CAV2 expression was observed in 13.4 and 5.9% of all breast cancer, respectively. Their expression was strongly associated with high histological grade, lack of steroid hormone receptor positivity (ER and PR), and expression of basal markers (basal cytokeratins, P63, P-cadherin). Furthermore, there was a significant association between CAV1 and CAV2 expression and basal-like phenotype. On univariate analysis only CAV2 had a prognostic impact on breast cancer-specific survival; however, this was not independent from other traditional markers on multivariate analysis. Our results demonstrate that both CAV1 and CAV2 are associated with basal-like phenotype. Further studies are warranted to determine whether they play an oncogenic role in basal-like/triple-negative breast cancer development or are just surrogate markers for this subgroup.Keywords
This publication has 57 references indexed in Scilit:
- Triple negative breast cancer: molecular profiling and prognostic impact in adjuvant anthracycline-treated patientsBreast Cancer Research and Treatment, 2007
- Distribution and significance of caveolin 2 expression in normal breast and invasive breast cancer: an immunofluorescence and immunohistochemical analysisBreast Cancer Research and Treatment, 2007
- Descriptive analysis of estrogen receptor (ER)‐negative, progesterone receptor (PR)‐negative, and HER2‐negative invasive breast cancer, the so‐called triple‐negative phenotypeCancer, 2007
- Prognostic markers in triple‐negative breast cancerCancer, 2006
- Morphological and immunophenotypic analysis of breast carcinomas with basal and myoepithelial differentiationThe Journal of Pathology, 2006
- Phenotypic evaluation of the basal-like subtype of invasive breast carcinomaLaboratory Investigation, 2005
- High‐throughput protein expression analysis using tissue microarray technology of a large well‐characterised series identifies biologically distinct classes of breast cancer confirming recent cDNA expression analysesInternational Journal of Cancer, 2005
- Expression of luminal and basal cytokeratins in human breast carcinomaThe Journal of Pathology, 2004
- Breast cancer classification and prognosis based on gene expression profiles from a population-based studyProceedings of the National Academy of Sciences, 2003
- Repeated observation of breast tumor subtypes in independent gene expression data setsProceedings of the National Academy of Sciences, 2003